NCT03383679: Study on Androgen Receptor and Triple Negative Breast Cancer

NCT03383679
Breast Cancer Type: Triple Negative
Hormone Mutations: AR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Endocrine (Hormone) Therapy, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients must have AR+ tumor(s)
Exclusions: Patients with active unstable brain metastases or leptomeningeal disease- See trial for details
https://ClinicalTrials.gov/show/NCT03383679

Comments are closed.

Up ↑